Exelixis has appointed Goldman Sachs to help review acquisition offers, Bloomberg reports. Various large pharmaceutical companies have shown interest in the U.S. drug maker. The biotechnology company lost $92.3 million in 2010 and has accumulated net loss totaling almost $1.2 billion since it launched in 2000. Exelixis raised $179 million in its most recent offering, completed last month.

Click here for the story from Bloomberg.